Schwab Carlton L, English Diana P, Roque Dana M, Pasternak Monica, Santin Alessandro D
Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
Immunotherapy. 2014;6(12):1279-93. doi: 10.2217/imt.14.90.
Ovarian cancer is the leading cause of death from gynecologic malignancy in the US. Treatments have improved with conventional cytotoxic chemotherapy and advanced surgical techniques but disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune system and its ability to recognize and eliminate microscopic disease is paramount in preventing recurrence. Ovarian cancer immunotherapy is targeting tumors through active, passive and adoptive approaches. The goal of immunotherapy is to balance the activation of the immune system against cancer while preventing the potential for tremendous toxicity elicited by immune modulation. In this paper we will review the different immunotherapies available for ovarian cancer as well as current ongoing studies and potential future directions.
卵巢癌是美国妇科恶性肿瘤死亡的主要原因。传统的细胞毒性化疗和先进的手术技术已使治疗有所改善,但疾病复发很常见,且几乎在所有病例中都是致命的。目前的证据表明,免疫系统及其识别和消除微小疾病的能力在预防复发方面至关重要。卵巢癌免疫疗法正通过主动、被动和过继性方法靶向肿瘤。免疫疗法的目标是在激活免疫系统对抗癌症的同时,平衡防止免疫调节引发巨大毒性的可能性。在本文中,我们将综述可用于卵巢癌的不同免疫疗法,以及当前正在进行的研究和潜在的未来方向。